In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month. XBI proceeded to rattle off a 4% win for June and is up 7.3% in July already. Where do the ETF's top holdings stand?The shares of EXACT Sciences Corporation (NASDAQ:EXAS) are down 1.1% to trade at $49.14 today. Despite bouncing 21% off its June 25 annual lows of $40.62, the cancer diagnostics stock is 33.5% lower in 2024. Sarepta Therapeutics Inc (NASDAQ:SRPT) stock is 1.8% lower to trade at ...

Investors shouldn't rush to buy the stock based on rosy short-term price targets.To say that Exact Sciences (EXAS 3.19%) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street.Cathie Wood is one of them. The investment firm she heads, Ark Invest, holds over 330,000 shares of Exact Sciences. She isn't the only one who isn't giving up on the company. Analysts on Wal ...

We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year. Back-to-back years of double-digit gains make finding stocks that can continue on such a torrid trajectory difficult.Yet analysts at Jefferies Financial Group (NYSE:JEF) have zeroed in on a handful of stocks they think can maintain that pace. Within the past two weeks, they plucked these three stocks for double-digit returns over the next 12 months. ...

A month has gone by since the last earnings report for Exact Sciences (EXAS) . Shares have lost about 17.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Exact Sciences Q1 Revenues Rise Y/Y, Gross ...

Exact Sciences (EXAS) continues to be impacted by escalating expenses and fierce competition.Exact Sciences has been grappling with escalated expenses for a while. Deteriorating international trade stemming from complex geopolitical environments across the globe is leading to a tough situation related to raw material and labor costs as well as freight charges. The stock carries a Zacks Rank #4 (Sell) currently.Further, the continuous rise in interest rates through 2023 with no news from the Fed of a rate cu ...

Exact Sciences Corporation (EXAS) will present 10 abstracts demonstrating the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to Jun 4, 2024. The data that will be provided expands the body of evidence surrounding the predictive and prognostic utility of the Oncotype DX test in all racial and ethnically diverse patients.Exact Sciences will also present data on their approach to multi-canc ...

With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will eventually happen, the market is content to run higher. With the benchmark index up 11% year-to-date (YTD), it is 48% higher since the bull began charging in 2022.There could be more to come. Much more. Bear markets tend to be short-term events lasting about 15 months on average. However, bull markets are measured in years. They ...

ARK创新ETF - ARK创新ETF集中投资于35至55只股票，专注于潜力巨大的公司[2] Verve Therapeutics - Verve Therapeutics致力于开发基因编辑疗法治疗心血管疾病[4] Verve计划 - Verve计划在2024年推进其研发项目，包括VERVE-101的Heart-1试验[6][7]

Exact Sciences Corporation (EXAS) reported a net loss of 50 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. This quarter's loss was wider than the year-ago loss of 42 cents.Revenues in DetailFirst-quarter consolidated revenues were $637.5 million, up 5.8% on reported and core revenue basis year over year. The metric exceeded the Zacks Consensus Estimate by 2%.Segments in DetailScreening revenues, including laboratory service revenues from Cologuard, PreventionGenetics and i ...

财务数据和关键指标变化 - 第一季度收入为6.38亿美元,同比增长6%,其中筛查业务收入为4.75亿美元,增长7% [13][14] - 精准肿瘤业务收入为1.63亿美元,增长5%,其中Oncotype DX全球增长7% [14] - 第一季度GAAP毛利率为70%,非GAAP毛利率为73%,略低于去年同期 [15] - 净亏损1.1亿美元,调整后EBITDA为3900万美元 [16] - 第一季度自由现金流为负1.2亿美元,符合预期和季节性趋势 [17] - 公司现金及证券余额为6.52亿美元,4月份完成债务再融资,现金增加至9.12亿美元 [18] 各条业务线数据和关键指标变化 - 筛查业务收入增长7%,两年复合增长率达24% [13] - Oncotype DX国际订单量同比增长超20% [14] - 公司计划未来18个月内推出多项新产品,包括OncoDetect、OncoLiquid等 [34] 各个市场数据和关键指标变化 - 日本、意大利和德国等市场Oncotype DX仍有巨大未满足需求 [32][33] - 美国Medicare人群中,传统Medicare仅占20%,Medicare Advantage已超过22%,为公司未来血液筛查测试提供增长机会 [94] 公司战略和发展方向及行业竞争 - 公司将继续投资高影响力的销售和营销机会,扩大销售团队规模 [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67] - 公司正在开发Cologuard 3.0,不断提升肠癌筛查的性能 [133] - 新进入者要进入筛查市场需要大量临床数据和获得质量指标纳入,这是一个漫长的过程 [58][59][60][61] - 公司在Oncotype DX方面拥有业内最丰富的临床数据和证据,处于领先地位 [138][139] 管理层对经营环境和未来前景的评论 - 公司有信心实现全年2.81-2.85亿美元的收入指引和3.25-3.5亿美元的调整后EBITDA指引 [20] - 第二季度总收入预计在6.77-6.97亿美元之间,其中筛查业务收入5.22-5.32亿美元,精准肿瘤业务收入1.55-1.65亿美元 [21] - 公司有信心未来几年实现双位数增长和持续盈利 [37] 问答环节重要的提问和回答 问题1 **Catherine Schulte 提问** 询问Cologuard业务的增长前景和毛利率变化 [41][42][43][44][45][46][47][48][49][50] **Kevin Conroy 和 Jeff Elliott 回答** 解释Cologuard业务增长的驱动因素,以及毛利率短期下降但长期将提升的原因 [42][43][44][45][46][47][48][49][50][51][52][53][54][55] 问题2 **Vijay Kumar 提问** 询问Cologuard业务的同比增长情况和竞争格局 [57][58][59][60][61] **Kevin Conroy 回答** 解释Cologuard和Cologuard Plus的性能优势,以及新进入者要进入市场的挑战 [58][59][60][61] 问题3 **Doug Schenkel 提问** 询问第一季度Cologuard业务的具体情况,是否存在一些短期因素影响 [65][66][67][68][69][70][71][72][73][74] **Kevin Conroy 和 Jeff Elliott 回答** 解释第一季度Cologuard业务的具体情况,以及未来增长的信心来源 [68][69][70][71][72][73][74][75][76][77][78][79][80]